about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceEvaluating supervised HAART in late-stage HIV among drug users: a preliminary report.Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteersZidovudine and Lamivudine for HIV Infection.ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohortRole of MRP4 and MRP5 in biology and chemotherapy.Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patientsPharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health TransitionProgress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1.Thermal stability and decomposition kinetic studies of acyclovir and zidovudine drug compoundsRestoration of the antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cellsThe impact of pharmacogenetics on HIV therapy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discoveryAcute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.3'-azido-3'-deoxythymidine induces deletions in L5178Y mouse lymphoma cells.In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.PharmGKB summary: zidovudine pathwayEvaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Food affects Zidovudine concentration independent of effects on gastrointestinal absorption.Mechanisms and the clinical relevance of complex drug-drug interactionsPharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles of Zidovudine in Rats
P2860
Q27692040-77F2F30A-D69D-43AD-89C5-50E95F1AFD43Q33803069-A28FB0EE-84E5-4A72-89A0-FEFF75DE825DQ33980114-6EFDACD1-A1EE-4B16-B471-C434EFCE75C0Q34194561-62412CEF-B3F0-46E6-8CE3-79E5F2A38F6AQ34571645-FF4CCFE8-FB02-4D1C-B249-B500E86C8998Q34992424-B5C076AB-09AA-413E-B63E-685748469C23Q36053613-A280E751-E3E3-46A8-953D-C205F32F8F3BQ36105822-D519DB51-7490-4B8A-BA01-B361C8B118A5Q36370241-C5687AE1-A280-4EB5-A5D7-4A33C17B4CADQ36636485-8A082722-5C96-48B5-AE3C-A43BE7770E2FQ37085569-ACDE8FF3-121D-4F59-B6DE-337F4232C5EBQ37405140-335F5266-0683-4DDD-93BE-AF1C6433CE61Q38051400-6364F15D-FA4C-45E9-A153-7EBCB30E9BF5Q38705829-90EB15BE-474F-40BD-A683-FAD6DA8432ECQ40108634-F85DBD2C-C9DC-40D1-93C3-1A3C1FC63922Q40159469-28AEFDD3-F212-4E8C-A3F8-B2B5C7A44648Q40600601-3B648F02-49D5-4C20-A5FC-11A374934CC5Q41474530-3481F4C0-3EDF-4FFA-AF08-16EE856794DEQ44737065-0B2FAB07-C6CB-4ABF-9CC1-96358E0ABA27Q46930425-D8F917A4-2AD8-4130-9DB1-E85FC3961C2FQ57490721-7E7CD5EF-857B-4801-9D45-5CB0AC082561Q59060941-3331EA2C-3E5B-4680-96DC-F029023ADECA
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Metabolism of Zidovudine.
@en
type
label
Metabolism of Zidovudine.
@en
prefLabel
Metabolism of Zidovudine.
@en
P1433
P1476
Metabolism of Zidovudine
@en
P2093
P304
P356
10.1016/0306-3623(95)00047-X
P577
1995-11-01T00:00:00Z